GlassScriptPhysician profile
Srobona Mitra
NPI 1770601353
$4,625.19
in general payments reported to CMS, 2019-2025
40 companies · $747 in 2025
The $747 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $423 · 2020: $613 · 2021: $640 · 2022: $905 · 2023: $682 · 2024: $616 · 2025: $747.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,045.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,044.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $978.76 | 2019-2025 | Breztri, Farxiga, Flumist Quadrivalent |
| Abbott Laboratories | $682.19 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Abbvie INC. | $347.28 | 2020-2024 | |
| Kowa Pharmaceuticals America, INC. | $327.95 | 2019-2025 | Zoryve, Livalo |
| Novo Nordisk INC | $216.47 | 2019-2025 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $181.35 | 2019-2021 | |
| Hologic Sales and Service, LLC | $127.37 | 2022-2025 | Thinprep 2000 Processor |
| Amarin Pharma, INC. | $122.90 | 2020-2021 | |
| Lilly USA, LLC | $118.50 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $112.65 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Shield Therapeutics INC | $99.32 | 2023-2024 | Accrufer |
| Dexcom, INC. | $95.53 | 2024-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $89.69 | 2023-2024 | Gvoke Hypopen |
| Ibsa Pharma INC. | $81.21 | 2022-2025 | Tirosint, Licart, Flector |
| Pfizer INC. | $77.84 | 2019-2025 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Srobona Mitra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.